Peters R H, Jollow D J, Stuart R K
Department of Pharmacology, Medical University of South Carolina, Charleston 29425.
Cancer Res. 1991 May 15;51(10):2536-41.
To explain the sequence-dependent in vitro cytotoxic synergism between 4-hydroperoxycyclophosphamide (4-HC) and cisplatin in the K-562 human leukemia cell line, we have hypothesized that 4-HC decreases cellular glutathione (GSH) levels and that the resulting diminution of the cellular protective effect of GSH leads to the increased cytotoxicity of cisplatin. Exposure of K-562 cells to 4-HC resulted in a concentration- and time-dependent depletion of cellular GSH. To determine the effect of modulation of GSH levels on the toxicity of cisplatin, K-562 cells were exposed to buthionine sulfoximine (BSO) and/or GSH ethyl esters. Depletion of GSH to approximately 10% of control values by BSO potentiated the cytotoxicity of cisplatin, while rapid replenishment of GSH to within normal levels by GSH esters abolished the potentiation of BSO. Doubling cellular GSH by incubation with GSH esters protected against cisplatin cytotoxicity. Of importance, pretreatment of K-562 cells with BSO, in addition to increasing the cytotoxicity of 4-HC and cisplatin, abolished the synergism between the two drugs. The working hypothesis was also tested in two other cell lines in which the cytotoxic synergism between 4-HC and cisplatin was exhibited: the Raji cell line, a human lymphoblastic cell line, and the L1210-CPA cell line, a subclone of the murine L1210 leukemia with resistance to 4-HC. GSH levels in these two cell lines were not altered by incubation with concentrations of 4-HC at which the synergism was observed. In conclusion, the data for the K-562 cell line, indicating that (a) 4-HC depletes cellular GSH levels, (b) the lowering of cellular GSH levels enhances the toxicity of cisplatin, and (c) intact GSH stores are required for the synergism, strongly support the postulate that the cytotoxic synergism between 4-HC and cisplatin is modulated by GSH levels in this cell line. However, the lack of 4-HC-mediated depletion of GSH at concentrations of 4-HC resulting in cytotoxic synergism in the Raji and L1210-CPA cell line indicates that mechanisms other than modulation of GSH levels by 4-HC are responsible for the synergism in these cells.
为了解释4-氢过氧环磷酰胺(4-HC)和顺铂在K-562人白血病细胞系中序列依赖性的体外细胞毒性协同作用,我们推测4-HC可降低细胞内谷胱甘肽(GSH)水平,而GSH细胞保护作用的减弱会导致顺铂细胞毒性增加。将K-562细胞暴露于4-HC会导致细胞内GSH浓度和时间依赖性的消耗。为了确定GSH水平调节对顺铂毒性的影响,将K-562细胞暴露于丁硫氨酸亚砜胺(BSO)和/或GSH乙酯。BSO将GSH消耗至对照值的约10%可增强顺铂的细胞毒性,而GSH乙酯使GSH迅速补充至正常水平则消除了BSO的增强作用。与GSH乙酯孵育使细胞内GSH加倍可保护细胞免受顺铂细胞毒性的影响。重要的是,用BSO预处理K-562细胞,除了增加4-HC和顺铂的细胞毒性外,还消除了两种药物之间的协同作用。该工作假设也在另外两种表现出4-HC和顺铂细胞毒性协同作用的细胞系中进行了测试:Raji细胞系,一种人淋巴细胞系;以及L1210-CPA细胞系,一种对4-HC具有抗性的小鼠L1210白血病亚克隆。在观察到协同作用的4-HC浓度下孵育,这两种细胞系中的GSH水平未发生改变。总之,K-562细胞系的数据表明:(a)4-HC消耗细胞内GSH水平;(b)细胞内GSH水平降低会增强顺铂的毒性;(c)协同作用需要完整的GSH储备,这有力地支持了以下假设,即4-HC和顺铂之间的细胞毒性协同作用受该细胞系中GSH水平的调节。然而,在Raji和L1210-CPA细胞系中,在导致细胞毒性协同作用的4-HC浓度下缺乏4-HC介导的GSH消耗,这表明除了4-HC调节GSH水平之外的机制导致了这些细胞中的协同作用。